The LFB Group is a leader in the field of biopharmaceuticals, with a focus on chronic conditions in haemostasis, immunology and intensive care, as well as perinatal medicine.
LFB markets 23 biological medicinal products, and four new medicinal products are in advanced clinical development for registration in Europe or the United States in these fields.
Our human fibrinogen, CLOTTAFACT, was awarded the Prix Galien in 2011.
Cutting-edge medicines in major therapeutic areas
Several rare bleeding disorders, including haemophilia, von Willebrand disease and other clotting factor deficiencies, are treated by replacement of the missing protein.
LFB manufactures a range of products suitable for use in these conditions, although not all of them are available in the United Kingdom.
The treatment of rare, usually genetic, immune system disorders relies mainly on immune replacement and immunomodulation with immunoglobulin G (IgG).
Our intravenously administered immunoglobulins (IVIG) are used in a number of markets outside the United Kingdom.
Perinatal & Intensive care
Severe essential protein deficiencies can result in emergency situations in which patients require intensive care.
Our therapies for severe haemorrhage, thrombosis, blood volume expansion, and pregnancy complications may be suitable for use in these situations.